Tumor antigen-dependent and tumor antigen-independent activation of antitumor activity in T cells by a bispecific antibody-modified tumor vaccine

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Schirrmacher, Volker ^a,b   Fournier, Philippe ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Center of Immunology and Oncology (IOZK)   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATV NDV TUMOR VACCINE; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; CANCER VACCINE; CD28 ANTIGEN; CD3 ANTIGEN;

ADOPTIVE TRANSFER; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLONAL ANERGY; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEMORY T LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ANIMAL; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASM; NEWCASTLE DISEASE PARAMYXOVIRUS; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CANCER VACCINES; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASMS; NEWCASTLE DISEASE VIRUS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 79955116208     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/423781     Document Type: Review

References (57)

1. Silk A. W., Finn O. J., Cancer vaccines: a promising cancer therapy against all odds Future Oncology 2007 3 3 299 306 (Pubitemid 47018641)
2. Nagorsen D., Thiel E., Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer Clinical Cancer Research 2006 12 10 3064 3069 (Pubitemid 43837352)
3. Rosenberg S. A., Yang J. C., Restifo N. P., Cancer immunotherapy: moving beyond current vaccines Nature Medicine 2004 10 9 909 915 (Pubitemid 39273730)
4. Rivoltini L., Canese P., Huber V., Iero M., Pilla L., Valenti R., Fais S., Lozupone F., Casati C., Castelli C., Parmiani G., Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opinion on Biological Therapy 2005 5 4 463 476 (Pubitemid 40593331)
5. Demanet C., Mulder A., Deneys V., Worsham M. J., Maes P., Claas F. H., Ferrone S., Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood 2004 103 8 3122 3130 (Pubitemid 38451690)
6. Filaci G., Suciu-Foca N., CD8+ T suppressor cells are back to the game: are they players in autoimmunity? Autoimmunity Reviews 2002 1 5 279 283 (Pubitemid 38352570)
7. Jonuleit H., Schmitt E., The regulator T cell family: distinct subsets and their interrelations Journal of Immunology 2003 171 12 6323 6327 (Pubitemid 37532056)
8. Ben-Baruch A., Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators Seminars in Cancer Biology 2006 16 1 38 52 (Pubitemid 43139708)
9. Elliott R. L., Blobe G. C., Role of transforming growth factor beta in human cancer Journal of Clinical Oncology 2005 23 9 2078 2093 (Pubitemid 46211385)
10. Liu V. C., Wong L. Y., Jang T., Shah A. H., Park I., Yang X., Zhang Q., Lonning S., Teicher B. A., Lee C., Tumor evasion of the immune system by converting CD4CD25 T cells into CD4CD25 T regulatory cells: role of tumor-derived TGF- Journal of Immunology 2007 178 5 2883 2892 (Pubitemid 46333166)
11. Zhou J., Ye F., Chen H., Lv W., Gan N., The expression of interleukin-10 in patients with primary ovarian epithelial carcinoma and in ovarian carcinoma cell lines Journal of International Medical Research 2007 35 3 290 300 (Pubitemid 46971349)
12. Zou W., Immunosuppressive networks in the tumour environment and their therapeutic relevance Nature Reviews Cancer 2005 5 4 263 274 (Pubitemid 40488632)
13. Zhang X., Huang H., Yuan J., Sun D., Hou W. S., Gordon J., Xiang J., CD48 dendritic cells prime CD4 T regulatory 1 cells to suppress antitumor immunity Journal of Immunology 2005 175 5 2931 2937 (Pubitemid 41170510)
14. Terabe M., Matsui S., Park J.-M., Mamura M., Noben-Trauth N., Donaldson D. D., Chen W., Wahl S. M., Ledbetter S., Pratt B., Letterio J. J., Paul W. E., Berzofsky J. A., Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence Journal of Experimental Medicine 2003 198 11 1741 1752 (Pubitemid 37494166)
15. Nefedova Y., Huang M., Kusmartsev S., Bhattacharya R., Cheng P., Salup R., Jove R., Gabrilovich D., Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer Journal of Immunology 2004 172 1 464 474 (Pubitemid 38020502)
16. Prud'homme G. J., Piccirillo C. A., The inhibitory effects of transforming growth factor-beta-1 (TGF- 1) in autoimmune diseases Journal of Autoimmunity 2000 14 1 23 42 (Pubitemid 30080536)
17. Pakravan N., Hassan A. T., Hassan Z. M., Naturally occurring self-reactive CD4+CD25+ regulatory T cells: universal immune code Cellular Molecular Immunology 2007 4 3 197 201
18. Bretscher P., The two-signal model of lymphocyte activation twenty-one years later Immunology Today 1992 13 2 74 76
19. June C. H., Bluestone J. A., Nadler L. M., Thompson C. B., The B7 and CD28 receptor families Immunology Today 1994 15 7 321 331 (Pubitemid 24231747)
20. Matzinger P., Tolerance, danger, and the extended family Annual Review of Immunology 1994 12 991 1045 (Pubitemid 24140436)
21. Janeway C. A. Jr., The immune system evolved to discriminate infectious nonself from noninfectious self Immunology Today 1992 13 1 11 16
22. Alexander D. J., Calnek B. W., Barnes H. J., Beard C. W., McDougald L., Saif J. Y. M., Newcastle disease and other Paramyxoviridae infections Diseases of Poultry 1997 10th Ames, Iowa, USA Iowa State University 541 569
23. Aghi M., Martuza R. L., Oncolytic viral therapiesthe clinical experience Oncogene 2005 24 52 7802 7816 (Pubitemid 41670681)
24. Zeng J., Fournier P., Schirrmacher V., Induction of interferon- and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus Virology 2002 297 1 19 30 (Pubitemid 34734906)
25. Fournier P., Zeng J., Schirrmacher V., Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN- responses by viral protein or dsRNA International Journal of Oncology 2003 23 673 680
26. Taniguchi T., Takaoka A., The interferon- / system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors Current Opinion in Immunology 2002 14 1 111 116 (Pubitemid 34085114)
27. Le Bon A., Tough D. F., Links between innate and adaptive immunity via type I interferon Current Opinion in Immunology 2002 14 4 432 436 (Pubitemid 34671244)
28. Heicappell R., Schirrmacher V., Von Hoegen P., Ahlert T., Appelhans B., Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects International Journal of Cancer 1986 37 4 569 577 (Pubitemid 16108598)
29. Schirrmacher V., Heicappell R., Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity Clinical and Experimental Metastasis 1987 5 2 147 156 (Pubitemid 17109000)
30. Schirrmacher V., Haas C., Bonifer R., Ahlert T., Gerhards R., Ertel C., Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus Gene Therapy 1999 6 1 63 73 (Pubitemid 29043695)
31. Ahlert T., Sauerbrei W., Bastert G., Ruhland S., Bartik B., Simiantonaki N., Schumacher J., Hcker B., Schumacher M., Schirrmacher V., Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer Journal of Clinical Oncology 1997 15 4 1354 1366 (Pubitemid 27167367)
32. Schirrmacher V., Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory Cancer Immunology, Immunotherapy 2005 54 6 587 598 (Pubitemid 40613037)
33. Ockert D., Schirrmacher V., Beck N., Stoelben E., Ahlert T., Flechtenmacher J., Hagmller E., Buchcik R., Nagel M., Saeger H. D., Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma Clinical Cancer Research 1996 2 1 21 28 (Pubitemid 26042174)
34. Schirrmacher V., Ahlert T., Probstle T., Steiner H. H., Herold-Mende C., Gerhards R., Hagmuller E., Immunization with virus-modified tumor cells Seminars in Oncology 1998 25 6 677 696 (Pubitemid 28565548)
35. Karcher J., Dyckhoff G., Beckhove P., Reisser C., Brysch M., Ziouta Y., Helmke B. H., Weidauer H., Schirrmacher V., Herold-Mende C., Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells Cancer Research 2004 64 21 8057 8061 (Pubitemid 39446943)
36. Steiner H. H., Bonsanto M. M., Beckhove P., Brysch M., Geletneky K., Ahmadi R., Schuele-Freyer R., Kremer P., Ranaie G., Matejic D., Bauer H., Kiessling M., Kunze S., Schirrmacher V., Herold-Mende C., Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefits Journal of Clinical Oncology 2004 22 21 4272 4281 (Pubitemid 41185148)
37. Schulze T., Kemmner W., Weitz J., Wernecke K. D., Schirrmacher V., Schlag P. M., Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial Cancer Immunology, Immunotherapy 2009 58 1 61 69
38. Haas C., Ertel C., Gerhards R., Schirrmacher V., Introduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus International Journal of Oncology 1998 13 6 1105 1115 (Pubitemid 28551531)
39. Termeer C. C., Schirrmacher V., Brcker E. B., Becker J. C., Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells Cancer Gene Therapy 2000 7 2 316 323 (Pubitemid 30194568)
40. Nolte M. A., Van Olffen R. W., Van Gisbergen K. P. J. M., Van Lier R. A. W., Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology Immunological Reviews 2009 229 1 216 231
41. Yamamoto T., Hattori M., Yoshida T., Induction of T-cell activation or anergy determined by the combination of intensity and duration of T-cell receptor stimulation, and sequential induction in an individual cell Immunology 2007 121 3 383 391 (Pubitemid 46817360)
42. Aigner M., Janke M., Lulei M., Beckhove P., Fournier P., Schirrmacher V., An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins International Journal of Oncology 2008 32 4 777 789 (Pubitemid 351780588)
43. Haas C., Lulei M., Fournier P., Arnold A., Schirrmacher V., A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes International Journal of Cancer 2006 118 3 658 667 (Pubitemid 43076015)
44. Feuerer M., Beckhove P., Bai L., Solomayer E. F., Bastert G., Diel I. J., Pedain C., Oberniedermayr M., Schirrmacher V., Umansky V., Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow Nature Medicine 2001 7 4 452 458 (Pubitemid 32298548)
45. Barton G. M., Medzhitov R., Control of adaptive immune responses by Toll-like receptors Current Opinion in Immunology 2002 14 3 380 383 (Pubitemid 34327982)
46. Matzinger P., Tolerance, danger, and the extended family Annual Review of Immunology 1994 12 991 1045 (Pubitemid 24140436)
47. Forden C., Do T lymphocytes correlate danger signals to antigen? Medical Hypotheses 2004 62 6 898 906 (Pubitemid 38680355)
48. Kawai T., Akira S., Pathogen recognition with Toll-like receptors Current Opinion in Immunology 2005 17 4 338 344 (Pubitemid 40848534)
49. Schulz O., Diebold S. S., Chen M., Nslund T. I., Nolte M. A., Alexopoulou L., Azuma Y. T., Flavell R. A., Liljestrm P., Reis E Sousa C., Toll-like receptor 3 promotes cross-priming to virus-infected cells Nature 2005 433 7028 887 892 (Pubitemid 40314900)
50. Berg R. E., Forman J., The role of CD8+ T cells in innate immunity and in antigen non-specific protection Current Opinion in Immunology 2006 18 3 338 343
51. Marsland B. J., Nembrini C., Schmitz N., Abel B., Krautwald S., Bachmann M. F., Kopf M., Innate signals compensate for the absence of PKC- during in vivo CD8+ T cell effector and memory responses Proceedings of the National Academy of Sciences of the United States of America 2005 102 40 14374 14379 (Pubitemid 41429705)
52. Fournier P., Schirrmacher V., Randomized clinical studies of anti-tumor vaccination: state of the art in 2008 Expert Review of Vaccines 2009 8 1 51 66
53. Dhanji S., Teh S. J., Oble D., Priatel J. J., Teh H. S., Self-reactive memory-phenotype CD8+ T cells exhibit both MHC-restricted and non-MHC-restricted cytotoxicity: a role for the T-cell receptor and natural killer cell receptors Blood 2004 104 7 2116 2123 (Pubitemid 39297866)
54. Dhanji S., Teh H. S., IL-2-activated CD8CD44 cells express both adaptive and innate immune system receptors and demonstrate specificity for syngeneic tumor cells Journal of Immunology 2003 171 7 3442 3450 (Pubitemid 37254545)
55. Gollob J. A., Schnipper C. P., Orsini E., Murphy E., Daley J. F., Lazo S. B., Frank D. A., Neuberg D., Ritz J., Characterization of a novel subset of CD8+ T cells that expands in patients receiving interleukin-12 Journal of Clinical Investigation 1998 102 3 561 575 (Pubitemid 28376159)
56. Slavin S., Ackerstein A., Or R., Shapira M. Y., Gesundheit B., Askenasy N., Morecki S., Immunotherapy in high-risk chemotherapy-resistant patients with metastatic solid tumors and hematological malignancies using intentionally mismatched donor lymphocytes activated with rIL-2: a phase I study Cancer Immunology, Immunotherapy 2010 59 10 1511 1519
57. Schirrmacher V., Fournier P., Danger signals in tumor cells: a risk factor for autoimmune disease? Expert Review of Vaccines 2010 9 4 347 350